218 related articles for article (PubMed ID: 19669298)
1. Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B.
Piratvisuth T
Hepatol Int; 2008 Jun; 2(2):140-6. PubMed ID: 19669298
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
3. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
4. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adefovir dipivoxil and pegylated interferon alpha-2a treatment in chronic hepatitis B patients.
Korkmaz P; Usluer G; Ozgunes I; Kartal ED; Erben N; Alpat SN
North Clin Istanb; 2014; 1(1):26-32. PubMed ID: 28058298
[TBL] [Abstract][Full Text] [Related]
6. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
Han SH
Drugs; 2006; 66(14):1831-51. PubMed ID: 17040114
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacotherapy for the treatment of chronic hepatitis B.
Lagget M; Rizzetto M
Expert Opin Pharmacother; 2003 Oct; 4(10):1821-7. PubMed ID: 14521491
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
9. Management of patients with chronic hepatitis B.
Liaw YF
J Gastroenterol Hepatol; 2002 Apr; 17(4):406-8. PubMed ID: 11982720
[TBL] [Abstract][Full Text] [Related]
10. Adefovir dipivoxil: a review of its use in chronic hepatitis B.
Dando T; Plosker G
Drugs; 2003; 63(20):2215-34. PubMed ID: 14498759
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
12. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis B infection using interferon.
Guan R
Med J Malaysia; 2005 Jul; 60 Suppl B():28-33. PubMed ID: 16108170
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.
You J; Zhuang L; Cheng HY; Yan SM; Yu L; Huang JH; Tang BZ; Huang ML; Ma YL; Chongsuvivatwong V; Sriplung H; Geater A; Qiao YW; Wu RX
World J Gastroenterol; 2006 Nov; 12(41):6715-21. PubMed ID: 17075991
[TBL] [Abstract][Full Text] [Related]
15. The curative effect of adefovir dipivoxil treating HBeAg negative chronic hepatitis B and treating HBeAg positive chronic hepatitis B combining interferon α-2b.
Gu J; Sun R; Shen S; Yu Z
Pak J Pharm Sci; 2015 Jul; 28(4 Suppl):1493-7. PubMed ID: 26431662
[TBL] [Abstract][Full Text] [Related]
16. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Hadziyannis SJ
Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
[TBL] [Abstract][Full Text] [Related]
17. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
18. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
[TBL] [Abstract][Full Text] [Related]
19. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
